Evogene Ltd
NASDAQ:EVGN
Evogene Ltd
Other Items
Evogene Ltd
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Evogene Ltd
NASDAQ:EVGN
|
Other Items
$16.7m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
7%
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Other Items
$8k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-46%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Other Items
$11.5m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Other Items
$94.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Other Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Matricelf Ltd
TASE:MTLF
|
Other Items
₪9.9m
|
CAGR 3-Years
635%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Evogene Ltd
Glance View
Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
See Also
What is Evogene Ltd's Other Items?
Other Items
16.7m
USD
Based on the financial report for Sep 30, 2025, Evogene Ltd's Other Items amounts to 16.7m USD.
What is Evogene Ltd's Other Items growth rate?
Other Items CAGR 10Y
7%
Over the last year, the Other Items growth was 2 386%. The average annual Other Items growth rates for Evogene Ltd have been -1% over the past three years , -13% over the past five years , and 7% over the past ten years .
